Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350256 · ClinicalTrials.gov registry record · NA
BurstDR™ micrOdosing stimuLation in De-novo Patients
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT03350256 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 60 participants.
The verdict
NCT03350256, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the therapeutic efficacy of microdosing BurstDR stimulation in spinal cord stimulation (SCS) patients with chronic intractable back and/or leg pain.
Interventions
- DEVICE Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2019-07-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03350256
The ClinicalTrials.gov registry entry for NCT03350256 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient. is the first listed.
NCT03350256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03350256 about?
NCT03350256 is a clinical study titled "BurstDR™ micrOdosing stimuLation in De-novo Patients". The purpose of this study is to evaluate the therapeutic efficacy of microdosing BurstDR stimulation in spinal cord stimulation (SCS) patients with chronic intractable back and/or leg pain.
What is the current status of trial NCT03350256?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2017-10-30. Estimated completion is 2019-07-02.
What interventions are being tested in trial NCT03350256?
The interventions under investigation include: Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient. (DEVICE).
Who is sponsoring clinical trial NCT03350256?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.